Page 82 - Vitamin D and Cancer

3 Anti-inflammatory Activity of Calcitriol in Cancer 69

use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch Intern Med
169(2):141–149
88. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB,
Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ (2000) Comparison of upper gastroin-
testinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR
Study Group. N Engl J Med 343(21):1520–1528
89. Krishnan AV, Srinivas S, Feldman D (2009) Inhibition of prostaglandin synthesis and actions
contributes to the beneficial effects of calcitriol in prostate cancer. Dermatoendocrinol
1(1):7–11
90. Johnson CS, Hershberger PA, Trump DL (2002) Vitamin D-related therapies in prostate
cancer. Cancer Metastasis Rev 21(2):147–158
91. Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH,
Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano
CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW (2007) Double-blinded ran-
domized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel
in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin
Oncol 25(6):669–674
92. Release NP. Novacea announces preliminary findings from data analysis of Ascent-2 Phase
3 trial. June 04, 2008
93. Release NP. Novacea update on Asentar(TM). September 11, 2008
94. Srinivas S, Feldman D (2008) A phase II trial of calcitriol and naproxen in recurrent prostate
cancer. Anticancer Res 29:3605–3610
95. Park JI, Lee MG, Cho K, Park BJ, Chae KS, Byun DS, Ryu BK, Park YK, Chi SG (2003)
Transforming growth factor-beta1 activates interleukin-6 expression in prostate cancer cells
through the synergistic collaboration of the Smad2, p38-NF-kappaB, JNK, and Ras signaling
pathways. Oncogene 22(28):4314–4332
96. Culig Z, Steiner H, Bartsch G, Hobisch A (2005) Interleukin-6 regulation of prostate cancer
cell growth. J Cell Biochem 95(3):497–505
97. Rose-John S, Schooltink H (2007) Cytokines are a therapeutic target for the prevention of
inflammation-induced cancers. Recent Results Cancer Res 174:57–66
98. Kai H, Kitadai Y, Kodama M, Cho S, Kuroda T, Ito M, Tanaka S, Ohmoto Y, Chayama K
(2005) Involvement of proinflammatory cytokines IL-1beta and IL-6 in progression of
human gastric carcinoma. Anticancer Res 25(2A):709–713
99. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, Lahm H (2000) Interleukin-6
stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer
Lett 151(1):31–38
100. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorec-
tal cancer. J Surg Oncol 83(4):222–226
101. Lyon DE, McCain NL, Walter J, Schubert C (2008) Cytokine comparisons between women
with breast cancer and women with a negative breast biopsy. Nurs Res 57(1):51–58
102. Tumminello FM, Badalamenti G, Incorvaia L, Fulfaro F, D’Amico C, Leto G (2009) Serum
interleukin-6 in patients with metastatic bone disease: correlation with cystatin C. Med
Oncol 26(1):10–15
103. Karin M, Lin A (2002) NF-kappaB at the crossroads of life and death. Nat Immunol
3(3):221–227
104. Ghosh S, Karin M (2002) Missing pieces in the NF-kappaB puzzle. Cell 109(Suppl):S81–S96
105. Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD (1999) Constitutive
activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by
ibuprofen. Oncogene 18(51):7389–7394
106. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE
(1997) Aberrant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer.
J Clin Invest 100(12):2952–2960